These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22824101)

  • 1. Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant.
    Heppenstall C; Bunce S; Smith JC
    Nutr J; 2012 Jul; 11():50. PubMed ID: 22824101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination cannabinoid and opioid receptor antagonists improves metabolic outcomes in obese mice.
    Lockie SH; Stefanidis A; Tschöp MH; Oldfield BJ
    Mol Cell Endocrinol; 2015 Dec; 417():10-9. PubMed ID: 26360587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
    Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H
    Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.
    Scheen AJ; Finer N; Hollander P; Jensen MD; Van Gaal LF;
    Lancet; 2006 Nov; 368(9548):1660-72. PubMed ID: 17098084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
    Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
    JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A High-Carbohydrate, High-Fiber, Low-Fat Diet Results in Weight Loss among Adults at High Risk of Type 2 Diabetes.
    Sylvetsky AC; Edelstein SL; Walford G; Boyko EJ; Horton ES; Ibebuogu UN; Knowler WC; Montez MG; Temprosa M; Hoskin M; Rother KI; Delahanty LM;
    J Nutr; 2017 Nov; 147(11):2060-2066. PubMed ID: 28954840
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of chronic oral rimonabant administration on energy budgets of diet-induced obese C57BL/6 mice.
    Zhang LN; Gamo Y; Sinclair R; Mitchell SE; Morgan DG; Clapham JC; Speakman JR
    Obesity (Silver Spring); 2012 May; 20(5):954-62. PubMed ID: 22173576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between pretreatment dietary composition and weight loss during a randomised trial of different diet approaches.
    McVay MA; Jeffreys AS; King HA; Olsen MK; Voils CI; Yancy WS
    J Hum Nutr Diet; 2015 Feb; 28 Suppl 2():16-23. PubMed ID: 24251378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
    Ruilope LM; Després JP; Scheen A; Pi-Sunyer X; Mancia G; Zanchetti A; Van Gaal L
    J Hypertens; 2008 Feb; 26(2):357-67. PubMed ID: 18192851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition.
    Koolman AH; Bloks VW; Oosterveer MH; Jonas I; Kuipers F; Sauer PJ; van Dijk G
    Int J Obes (Lond); 2010 Feb; 34(2):374-84. PubMed ID: 19844210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes.
    Boden G; Sargrad K; Homko C; Mozzoli M; Stein TP
    Ann Intern Med; 2005 Mar; 142(6):403-11. PubMed ID: 15767618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP; Golay A; Sjöström L;
    N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial.
    Hollander PA; Amod A; Litwak LE; Chaudhari U;
    Diabetes Care; 2010 Mar; 33(3):605-7. PubMed ID: 20009090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal vs. high-protein weight loss diets in men: effects on body composition and indices of metabolic syndrome.
    Tang M; Armstrong CL; Leidy HJ; Campbell WW
    Obesity (Silver Spring); 2013 Mar; 21(3):E204-10. PubMed ID: 23592676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
    Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
    Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High protein weight loss diets in obese subjects with type 2 diabetes mellitus.
    Pedersen E; Jesudason DR; Clifton PM
    Nutr Metab Cardiovasc Dis; 2014 May; 24(5):554-62. PubMed ID: 24374004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty acid flux and oxidation are increased by rimonabant in obese women.
    Backhouse K; Sarac I; Shojaee-Moradie F; Stolinski M; Robertson MD; Frost GS; Bell JD; Thomas EL; Wright J; Russell-Jones D; Umpleby AM
    Metabolism; 2012 Sep; 61(9):1220-3. PubMed ID: 22445512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of rimonabant in obese patients with binge eating disorder.
    Pataky Z; Gasteyger C; Ziegler O; Rissanen A; Hanotin C; Golay A
    Exp Clin Endocrinol Diabetes; 2013 Jan; 121(1):20-6. PubMed ID: 23147209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.